Table 3.
Demographic, Treatment, and Health Characteristics of SJLIFE Sample (n=897)a
| Variable | Short Sleep Duration n=400 | Typical Sleep Duration n=495 | Pe | |
|---|---|---|---|---|
| M (SD) | M (SD) | |||
| Age at evaluation, years | 35.1 (8.5) | 33.8 (9.2) | 0.0397 | |
| Age at diagnosis, years | 8.6 (5.7) | 8.8 (5.6) | 0.5239 | |
| BMI, amputation adjusted (kg/m2) | 29.4 (7.5) | 28.2 (6.7) | 0.0137 | |
| N (%) | N (%) | |||
| Sex | ||||
| Female | 212 (53.0) | 252 (50.9) | 0.5337 | |
| Male | 188 (47.0) | 243 (49.1) | ||
| Race/Ethnicity | ||||
| White, non-Hispanic | 324 (81.0) | 429 (86.7) | 0.0211 | |
| Other | 76 (19.0) | 66 (13.3) | ||
| Diagnosis | ||||
| Leukemia | 150 (37.5) | 220 (44.4) | 0.0945 | |
| CNS tumor | 24 (6.0) | 42 (8.5) | ||
| Non-CNS solid tumor | 108 (27.0) | 101 (20.6) | ||
| Hodgkin lymphoma | 51 (12.8) | 66 (13.4) | ||
| Non-Hodgkin lymphoma | 28 (7.0) | 28 (5.7) | ||
| Ewing/osteosarcoma | 32 (8.0) | 29 (5.9) | ||
| Other | 7 (1.8) | 8 (1.6) | ||
| Radiation | ||||
| Cranial radiation | ||||
| ≥ 20 Gy | 58 (12.3) | 80 (16.9) | 0.5078 | |
| < 20 Gy | 44 (11.5) | 56 (11.9) | ||
| No cranial radiation | 285 (74.2) | 335 (70.8) | ||
| Chest radiation | 72 (18.7) | 111 (23.5) | 0.0865 | |
| Abdominal radiation | 67 (17.4) | 95 (20.1) | 0.3095 | |
| Neck radiation | 65 (16.8) | 109 (23.0) | 0.0244 | |
| Chemotherapy | ||||
| High dose IV methotrexate | 118 (29.5) | 162 (32.7) | 0.3005 | |
| Intrathecal methotrexate/cytarabine | 167 (41.8) | 225 (45.5) | 0.2667 | |
| Corticosteroids | 202 (50.5) | 269 (54.3) | 0.2522 | |
| Anthracyclines | 246 (61.5) | 320 (64.7) | 0.3317 | |
| Alkylating agents (classic) | 232 (58.0) | 300 (60.6) | 0.4299 | |
| Alkylating agents (heavy metal) | 37 (9.3) | 48 (9.7) | 0.8206 | |
| Ifosfamide | 29 (7.3) | 37 (7.5) | 0.8982 | |
| Physically inactiveb,c | 162 (47.7) | 183 (42.2) | 0.1279 | |
| Psychological distressd,c | ||||
| BSI anxiety | 35 (10.6) | 13 (3.4) | <0.0001 | |
| BSI depression | 34 (10.3) | 20 (5.2) | 0.0100 | |
| Chronic conditions | ||||
| Cardiac conditions (Grade ≥2) | 173 (43.3) | 192 (38.8) | 0.1768 | |
| Endocrine conditions (Grade ≥2) | 223 (55.8) | 225 (45.5) | 0.0022 | |
| Pulmonary conditions (Grade ≥2) | 121 (30.3) | 114 (23.0) | 0.0147 | |
| Renal conditions (Grade ≥2) | 46 (11.5) | 43 (8.7) | 0.1621 | |
| Neurologic conditions (Grade ≥2) | 130 (32.5) | 147 (29.7) | 0.3671 | |
| Gastrointestinal conditions (Grade ≥2) | 148 (37.0) | 130 (26.3) | 0.0006 | |
| Musculoskeletal conditions (Grade ≥2) | 123 (30.8) | 146 (29.5) | 0.6839 | |
CNS, central nervous system; GY, gray; IV, intravenous; BSI, Brief Symptom Inventory; M, mean; SD, standard deviation
a
Participants with long sleep duration removed (n=14)
b
Physically inactive was defined according to CDC criteria of 450 MET-minutes per week
c
Psychological distress defined as T-score ≥63
d
The following variables had >10% missing: physically inactive (n=121); anxiety and depression (n=182)
e
Chi-square test or t-test for comparison of continuous variables between short and typical sleep duration groups, all tests were two-sided